The US FDA has issued Sun Pharmaceutical Industries with a Form 483 citing problems identified at its plant in Halol.
The WHO has agreed to source drugs from manufacturers which use sustainable production methods.
AmerisourceBergan has warned of the dangers of reimportation a day after the Senate rejected Bernie Sanders’ “Trump proposal” to overturn the ban.
Mylan NV has announced a restructuring plan that it says will impact less than 10% of its workforce.
Fareva Group has set up an aerosol manufacturing facility at its site in Richmond, Virginia as part of a $40m (€37m) investment in its drug, OTC medicine and beauty care business.
Lonza has agreed to sell its therapeutic peptide business to PolyPeptide Laboratories in a deal that will also see the latter firm take on 280 staff.
The US FDA has asked Spanish API firm Interquim S.A. for more details of its plan to bring its Barcelona manufacturing plant up to code.
The development partnership has been extended as GlaxoSmithKline looks to make clinical trial scale batches using Puridify’s Protein A alternative to packed bed chromatography columns.